Bafna Pharmaceuticals is going to hit the capital market with an initial public offering of 64,00,000 equity shares of Rs10 each for cash at a premium of Rs30 per share. The issue will open on May 27 and will close on May 30.
The company will utilise the proceeds for building brand in the domestic and international markets. It would also strengthen its R&D facility at Grantlayon plant.
The company is engaged in the manufacturing of Betalactum and non-Betalactum pharmaceutical formulations in tablets, capsules and liquid forms. It manufactures 126 formulations under various therapeutic segments such as anti-infectiv, cholesterol lowering agents, analgesic and antipyretic, antihelmintics, appetite stimulants, cough and cold preparations, anti-ulcerants and anti diabetic, vitamins.
The company will utilise the proceeds for building brand in the domestic and international markets. It would also strengthen its R&D facility at Grantlayon plant.
The company is engaged in the manufacturing of Betalactum and non-Betalactum pharmaceutical formulations in tablets, capsules and liquid forms. It manufactures 126 formulations under various therapeutic segments such as anti-infectiv, cholesterol lowering agents, analgesic and antipyretic, antihelmintics, appetite stimulants, cough and cold preparations, anti-ulcerants and anti diabetic, vitamins.
No comments:
Post a Comment